Evidence map›Paper›PMID 41156702›Full record

ArticleMicroorganisms2025

Remdesivir: Effectiveness and Safety in Hospitalized COVID-19 Patients-Analysis of Retrospectively Collected Data from Daily Practice in the Omicron Variant Era and Comparison with the Pre-Omicron Period.

Nikos Pantazis, Evmorfia Pechlivanidou, Vassiliki Rapti, Dimitra Kavatha, Haralampos Milionis, Ioannis Kalomenidis, Karolina Akinosoglou, Periklis Panagopoulos, Symeon Metallidis, Diamantis Kofteridis and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Nikos PantazisDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-4196-5066
Evmorfia PechlivanidouDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-0492-2550
Vassiliki Rapti3rd Department of Internal Medicine, Athens Hospital for Diseases of the Chest "Sotiria", Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-8322-635X
Dimitra Kavatha4th Department of Internal Medicine, Attikon University General Hospital, Medical School, National & Kapodistrian University of Athens, 12462 Athens, Greece.
Haralampos MilionisDepartment of Internal Medicine, University General Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0003-3958-2266
Ioannis Kalomenidis1st Department of Critical Care & Pulmonary Service, Evangelismos General Hospital, Medical School, National & Kapodistrian University of Athens, 10676 Athens, Greece.
Karolina AkinosoglouDepartment of Internal Medicine, University General Hospital of Patras, Department of Medicine, University of Patras, 26504 Rio, Greece.ORCID 0000-0002-4289-9494
Periklis PanagopoulosDepartment of Internal Medicine, University General Hospital of Alexandroupolis, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Symeon Metallidis1st Department of Internal Medicine, AHEPA University General Hospital, Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Diamantis KofteridisDepartment of Internal Medicine, University General Hospital of Herakleion, Faculty of Medicine, School of Health Sciences, University of Crete, 71110 Herakleion, Greece.ORCID 0000-0003-0255-5926
Nikolaos V SipsasInfectious Diseases and COVID-19 Unit, Laiko General Hospital, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-6955-3453
Ioannis KatsarolisMedical Affairs, Gilead Sciences Hellas and Cyprus, 17564 Paleo Faliro, Greece.
Garyfallia Poulakou3rd Department of Internal Medicine, Athens Hospital for Diseases of the Chest "Sotiria", Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0003-0778-0006
Anastasia Antoniadou4th Department of Internal Medicine, Attikon University General Hospital, Medical School, National & Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0003-0991-9198
Eirini ChristakiDepartment of Internal Medicine, University General Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Theofani Rimpa1st Department of Critical Care & Pulmonary Service, Evangelismos General Hospital, Medical School, National & Kapodistrian University of Athens, 10676 Athens, Greece.ORCID 0000-0002-2665-6003
Markos MarangosDepartment of Internal Medicine, University General Hospital of Patras, Department of Medicine, University of Patras, 26504 Rio, Greece.
Vasileios PetrakisDepartment of Internal Medicine, University General Hospital of Alexandroupolis, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Olga Tsachouridou1st Department of Internal Medicine, AHEPA University General Hospital, Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Vasiliki E GeorgakopoulouInfectious Diseases and COVID-19 Unit, Laiko General Hospital, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0003-0772-811X
Pinelopi Kazakou4th Department of Internal Medicine, Attikon University General Hospital, Medical School, National & Kapodistrian University of Athens, 12462 Athens, Greece.
Sotirios P Karagiannis1st Department of Critical Care & Pulmonary Service, Evangelismos General Hospital, Medical School, National & Kapodistrian University of Athens, 10676 Athens, Greece.ORCID 0000-0002-2823-5675
Eleni PolyzouDepartment of Internal Medicine, University General Hospital of Patras, Department of Medicine, University of Patras, 26504 Rio, Greece.
Giota TouloumiDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-5951-0844

Funding

Gilead Sciences, Inc. - Investigator-Sponsored Research Grant Program CO-GR-540-6245
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has impacted global health. Remdesivir was approved based on clinical trials demonstrating improved outcomes in hospitalized patients. The ReEs-COVID19 study provides real-world evidence on its effectiveness and safety across two periods: Pre-Omicron and Omicron. This retrospective, observational cohort study included 1610 patients hospitalized with COVID-19, treated with remdesivir during Pre-Omicron (September 2020-February 2021; n = 606) and Omicron (June 2022-March 2023; n = 1004) periods. Primary endpoint: time to discharge; Hepatic/renal function abnormalities were also investigated. In the Omicron period patients were older and had more comorbidities but remdesivir was initiated earlier (median: 2 days from symptom onset) compared to the Pre-Omicron period (8 days). ICU admissions rates and direct COVID-19-related deaths were significantly lower, but overall 30-day mortality was higher during the Omicron period. Earlier remdesivir administration was associated with faster discharge. Abnormal liver tests and acute kidney injury were rare across both periods. ReEs-COVID19 confirmed remdesivir's effectiveness and safety in real-world clinical settings during both periods, underscoring its importance in treatment of hospitalized COVID-19 patients, especially when initiated earlier in the disease course. Further research is needed to evaluate its utility in specific subgroups (e.g., immuno-compromised) and in combination with other treatments.

Indexed as

COVID-19efficacyhospitalized patientsOmicronPre-Omicron vs. Omicronremdesivirsafety

Identifiers

PMID41156702
PMCPMC12566431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.